Anti-SasA Antibody Development

Creative Biolabs is the world leading service provider for the discovery and development of diagnostic as well as therapeutic antibodies. Based on our years of experience and advanced platform, we are confident in offering the best and most suitable antibody service against various protein biomarkers. With a deep understanding of the process of antibody discovery and development, Creative Biolabs provides antibody customization services for Staphylococcus aureus (S. aureus) surface protein A (SasA).

SasA Introduction

S.aureus is the most common cause of hospital-acquired bacteremia. Due to the emergence of multi-antibiotic resistant in Methicillin-Resistant S. aureus (MRSA), these infections pose serious health threatening to the public. It is urgent to develop novel therapeutics such as effective monoclonal antibodies (mAbs) to treat or prevent serious S. aureus infections. SasA, a cell wall-anchored protein of S. aureus, is one of MSCRAMMs (microbial surface components recognizing adhesive matrix molecules) and has been reported to be a virulence determinant in endovascular infections. SasA is prevalent in S. aureus clinical isolates and is expressed during S. aureus infections in vivo.

Structure of SasA

SasA is a large surface-located protein and composed of 2,271 amino acid residues with an molecular weight (MW) of approximately 240 kDa. It belongs to the serine-rich repeat proteins (SRRPs) family. There exists a conserved region of SasA among a diverse range of clinical S. aureus strains. SasA is mainly composed of a short serine-rich repeat region (SRR1), a basic amino acid region (BR), a second long serine-rich repeat region (SRR2) and a C-terminal cell wall anchor motif (CW). Sequence homology analysis showed that BR is the most conserved region of SasA.

Fig.1 Schematic representation of S. aureus SasA. (Kukita, 2013)

Antibody-Based Therapy

Considering SasA is prevalent and the NRR region is conserved among clinical S. aureus strains, SasA is a promising target for mAb-based immunotherapy against MRSA infections. Many reports have provided supporting evidence that an anti-SasA mAb might be a potential component the immunotherapeutic treatment of MRSA infections. However, immunotherapy with a single component of anti-SasA mAb is not competent for the combat against MRSA infections in all conditions. Passive immunization with mAbs and combined antibiotics is likely to provide enhanced protective efficacy against MRSA infections, thus antibody-antibiotic conjugate (AAC) can serve as a great potential treatment for those infections.

Creative Biolabs offers a complete custom antibody service covering every step of mAbs development. We produce and validate antibodies against a number of S. aureus surface proteins. Based on our year's experience and first-in-class instruments, Creative Biolabs gets ready to provide you with the best antibody services to promote your AAC project. Please feel free to contact us for more details.

References

1. Kukita, K.; et al. (2013). Staphylococcus aureus SasA is responsible for binding to salivary agglutinin, gp340, derived from human saliva. Infection and immunity, IAI-00011.

For Research Use Only. NOT FOR CLINICAL USE.